Health
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies | Vaccines | News Channels – PipelineReview.com
La Merie Publishing prepares brief and full reports as well as competitor analysis reports, the latter in a tabulated format with structured listings of industry-relevant data. One of our top-selling.
Details
Category: Vaccines
Published on Thursday, 30 July 2020 13:24
Hits: 538
NEW BRUNSWICK, NJ, USA I July 30, 2020 I Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company’s investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by “neutral…
-
Noosa News12 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General16 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
Business21 hours agoTop brokers name 3 ASX shares to buy next week 5 October 2025
-
Noosa News5 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership